Apligraf - an FDA-approved, bioengineered living-cell therapy from Organogenesis Inc. - has become the first wound-healing therapy to demonstrate a significant change in the genomic profile of a ...
This week, Organogenesis Inc. will present new mechanisms of action data from an Apligraf ® clinical study and in vitro / pre-clinical data evaluating mechanisms of healing for Dermagraft ® at the ...
CANTON, Mass., April 17, 2012 /PRNewswire/ -- Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that Apligraf® has established improved coverage from multiple ...
Apligraf® - an FDA-approved, bioengineered living-cell therapy from Organogenesis Inc. - has become the first wound-healing therapy to demonstrate a significant change in the genomic profile of a ...
Biotherapeutic Cell-based Product from Organogenesis Meets Switzerland's Highest Clinical and Safety Standards CANTON, Massachusettsand REINACH, Switzerland, Nov. 2, 2015 /PRNewswire/ --Organogenesis ...
Nov. 3, 2003 (New Orleans) — The skin substitute Apligraf is effective in closing wounds due to infection, burns, and trauma, potentially negating the need for donor grafts, researchers reported here ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. © 2026 American City Business Journals. All rights ...
Organogenesis, Inc. announced that its Apligraf® bilayered living cellular construct has been approved for the treatment of diabetic foot ulcers and other chronic wounds by the Saudi Food and Drug ...
Biotherapeutic Cell-based Product from Organogenesis Meets Switzerland's Highest Clinical and Safety Standards Apligraf is a biotherapeutic wound-healing technology that contains two layers of human ...
Organogenesis, Inc. announced that its Apligraf bilayered living cellular construct has been approved for the treatment of diabetic foot ulcers and other chronic wounds by the Saudi Food and Drug ...
CANTON, Mass. and ORLANDO, Fla., April 22, 2014 /PRNewswire/ -- This week, Organogenesis Inc. will present new mechanisms of action data from an Apligraf((R)) clinical study and in vitro / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results